Myrtle Potter has served as a member of Guardant Health’s board of directors since October 2021. Ms. Potter most recently served as President, Chief Executive Officer and Chairperson of the Board of Sumitovant Pharma America, Inc. from July 1, 2023 to April 1, 2024. Prior to this, Ms. Potter served as the Chief Executive Officer of Sumitovant Biopharma, Inc., a subsidiary of Sumitovant Biopharma Ltd., from December 2019 to July 2023, when Sumitomo Pharma America, Inc. announced its launch resulting from the combination of Sumitovant, its wholly owned U.S. subsidiaries and other U.S. Sumitomo Pharma wholly owned subsidiaries. Previously, Ms. Potter served as Vant Operating Chair at Roivant Sciences, Ltd. from 2018 to 2019, and as Chief Executive Officer of Myrtle Potter & Company, LLC from 2005 to 2018. Prior to this, Ms. Potter served as Chief Operating Officer at Genentech, Inc. from 2000 to 2004 and as the President, Commercial Operations and Executive Vice President of Genentech from 2004 to 2005. Prior to joining Genentech, she held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb and Vice President at Merck & Co.
Ms. Potter currently serves on the Board of Directors of Liberty Mutual Holding Company, Inc. Ms. Potter previously served on the Board of Directors of Myovant Sciences, Ltd., Urovant Sciences Ltd., Axsome Therapeutics, Inc., Everyday Health, Inc., Immunovant, Inc., Axovant Gene Therapies, Ltd., Arbutus Biopharma, Inc., Insmed Incorporated, Rite Aid Corporation and Amazon.com. Ms. Potter holds a Bachelor of Arts degree from The University of Chicago.
What is Myrtle S. Potter's net worth?
The estimated net worth of Myrtle S. Potter is at least $1.99 million as of October 17th, 2025. Ms. Potter owns 18,324 shares of Guardant Health stock worth more than $1,988,520 as of December 4th. This net worth estimate does not reflect any other assets that Ms. Potter may own. Learn More about Myrtle S. Potter's net worth.
How do I contact Myrtle S. Potter?
Has Myrtle S. Potter been buying or selling shares of Guardant Health?
In the last ninety days, Myrtle S. Potter has sold $1,740.70 in shares of Guardant Health stock. Most recently, Myrtle S. Potter sold 26 shares of the business's stock in a transaction on Friday, October 17th. The shares were sold at an average price of $66.95, for a transaction totalling $1,740.70. Following the completion of the sale, the director now directly owns 18,324 shares of the company's stock, valued at $1,226,791.80. Learn More on Myrtle S. Potter's trading history.
Who are Guardant Health's active insiders?
Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Medina Hidalgo (Director), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Myrtle Potter (Director), John Saia (Insider), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?
During the last year, insiders at the sold shares 33 times. They sold a total of 713,670 shares worth more than $42,038,200.84. The most recent insider tranaction occured on December, 1st when insider Terilyn J Monroe sold 55,167 shares worth more than $5,846,046.99. Insiders at Guardant Health own 6.1% of the company.
Learn More about insider trades at Guardant Health. Information on this page was last updated on 12/1/2025.
